BNTX vs. NVO: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BNTX and NVO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Both BNTX and NVO are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.
| Symbol | BNTX | NVO |
|---|---|---|
| Company Name | BioNTech SE | Novo Nordisk A/S |
| Country | Germany | Denmark |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 25.36 billion USD | 263.10 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | October 10, 2019 | April 30, 1981 |
| Security Type | ADR | ADR |
Historical Performance
This chart compares the performance of BNTX and NVO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BNTX | NVO |
|---|---|---|
| 5-Day Price Return | 7.53% | 6.50% |
| 13-Week Price Return | -4.10% | -17.76% |
| 26-Week Price Return | 15.85% | -27.57% |
| 52-Week Price Return | -11.35% | 67.26% |
| Month-to-Date Return | 6.97% | 7.69% |
| Year-to-Date Return | -7.42% | -40.54% |
| 10-Day Avg. Volume | 0.66M | 6.07M |
| 3-Month Avg. Volume | 0.93M | 6.51M |
| 3-Month Volatility | 37.93% | 63.79% |
| Beta | 1.34 | 1.56 |
Profitability
Return on Equity (TTM)
BNTX
-1.82%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
BNTX has a negative Return on Equity of -1.82%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
NVO
77.86%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
BNTX
-24.18%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
BNTX has a negative Net Profit Margin of -24.18%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
NVO
35.61%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 35.61% places NVO in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
BNTX
-47.77%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
BNTX has a negative Operating Profit Margin of -47.77%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
NVO
45.78%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
An Operating Profit Margin of 45.78% places NVO in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | BNTX | NVO |
|---|---|---|
| Return on Equity (TTM) | -1.82% | 77.86% |
| Return on Assets (TTM) | -1.57% | 24.22% |
| Net Profit Margin (TTM) | -24.18% | 35.61% |
| Operating Profit Margin (TTM) | -47.77% | 45.78% |
| Gross Profit Margin (TTM) | 84.90% | 83.95% |
Financial Strength
Current Ratio (MRQ)
BNTX
8.61
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
BNTX’s Current Ratio of 8.61 is in the upper quartile for the Biotechnology industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
NVO
0.78
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BNTX
0.01
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
BNTX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
NVO
0.59
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BNTX
-1.43
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
BNTX has a negative Interest Coverage Ratio of -1.43. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
NVO
149.07
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | BNTX | NVO |
|---|---|---|
| Current Ratio (MRQ) | 8.61 | 0.78 |
| Quick Ratio (MRQ) | 8.48 | 0.56 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.59 |
| Interest Coverage Ratio (TTM) | -1.43 | 149.07 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BNTX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BNTX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
NVO
3.10%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
NVO’s Dividend Yield of 3.10% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
BNTX
17.60%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 17.60%, BNTX’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
NVO
61.60%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | BNTX | NVO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 3.10% |
| Dividend Payout Ratio (TTM) | 17.60% | 61.60% |
Valuation
Price-to-Earnings Ratio (TTM)
BNTX
--
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
P/E Ratio data for BNTX is currently unavailable.
NVO
14.83
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 14.83 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
BNTX
7.78
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
BNTX’s P/S Ratio of 7.78 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
NVO
5.28
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
NVO’s P/S Ratio of 5.28 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
BNTX
1.18
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
BNTX’s P/B Ratio of 1.18 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
NVO
8.87
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | BNTX | NVO |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 14.83 |
| Price-to-Sales Ratio (TTM) | 7.78 | 5.28 |
| Price-to-Book Ratio (MRQ) | 1.18 | 8.87 |
| Price-to-Free Cash Flow Ratio (TTM) | 182.98 | 25.02 |